Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Prescription drug monitoring programs (PDMPs)
| Prescription drug monitoring programs (PDMPs) |
| Pubbl/distr/stampa | [Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration |
| Descrizione fisica | 1 online resource (1 unnumbered page) |
| Collana |
Rx pain medications: know the options, get the facts
SMA |
| Soggetto topico |
Drug monitoring
Pain medicine Drugs - Prescribing - Management Opioid abuse - Prevention Medication abuse - Prevention |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Prescription drug monitoring programs |
| Record Nr. | UNINA-9910716900703321 |
| [Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Prescription pain medication agreement
| Prescription pain medication agreement |
| Pubbl/distr/stampa | [Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration |
| Descrizione fisica | 1 online resource (1 unnumbered page) |
| Collana |
Rx pain medications: know the options, get the facts
SMA |
| Soggetto topico |
Patient education
Opioid abuse - Prevention Pain - Treatment - Management Pain medicine Drug monitoring |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910716898003321 |
| [Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Promoting safety of medicines for children [[electronic resource] /] / World Health Organization
| Promoting safety of medicines for children [[electronic resource] /] / World Health Organization |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2007 |
| Descrizione fisica | 1 online resource (64 p.) |
| Disciplina |
615.58083
615.58083615.542 |
| Soggetto topico |
Drugs - Safety measures
Drugs - Toxicology Drug monitoring Pediatric pharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-30747-5
9786611307479 92-4-068233-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Current situation -- The essential role of safety monitoring in the life-cycle of a medicine -- Medication errors -- Primary responsibility of stakeholders -- Guidance : measures to be taken -- Measures to be taken by WHO. |
| Record Nr. | UNINA-9910454187703321 |
| Geneva, : World Health Organization, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Promoting safety of medicines for children [[electronic resource] /] / World Health Organization
| Promoting safety of medicines for children [[electronic resource] /] / World Health Organization |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2007 |
| Descrizione fisica | 1 online resource (64 p.) |
| Disciplina |
615.58083
615.58083615.542 |
| Soggetto topico |
Drugs - Safety measures
Drugs - Toxicology Drug monitoring Pediatric pharmacology |
| ISBN |
1-281-30747-5
9786611307479 92-4-068233-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Current situation -- The essential role of safety monitoring in the life-cycle of a medicine -- Medication errors -- Primary responsibility of stakeholders -- Guidance : measures to be taken -- Measures to be taken by WHO. |
| Record Nr. | UNINA-9910782698003321 |
| Geneva, : World Health Organization, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Promoting safety of medicines for children [[electronic resource] /] / World Health Organization
| Promoting safety of medicines for children [[electronic resource] /] / World Health Organization |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2007 |
| Descrizione fisica | 1 online resource (64 p.) |
| Disciplina |
615.58083
615.58083615.542 |
| Soggetto topico |
Drugs - Safety measures
Drugs - Toxicology Drug monitoring Pediatric pharmacology |
| ISBN |
1-281-30747-5
9786611307479 92-4-068233-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Current situation -- The essential role of safety monitoring in the life-cycle of a medicine -- Medication errors -- Primary responsibility of stakeholders -- Guidance : measures to be taken -- Measures to be taken by WHO. |
| Record Nr. | UNINA-9910813919403321 |
| Geneva, : World Health Organization, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Recent advances in therapeutic drug monitoring and clinical toxicology / / Seth Kwabena Amponsah, Yashwant Vishnupant Pathak, editors
| Recent advances in therapeutic drug monitoring and clinical toxicology / / Seth Kwabena Amponsah, Yashwant Vishnupant Pathak, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (384 pages) |
| Disciplina | 615.9 |
| Soggetto topico |
Clinical toxicology
Drug monitoring |
| ISBN | 3-031-12398-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Contents -- About the Editors -- Contributors -- 1: Therapeutic and Toxic Concentrations of Drugs in Biological Matrices -- 1.1 Introduction -- 1.2 Therapeutic Drug Monitoring -- 1.3 Biological Matrices -- 1.3.1 Blood -- 1.3.2 Urine -- 1.3.3 Saliva -- 1.3.4 Cerebrospinal Fluid (CSF) -- 1.3.5 Hair -- 1.4 Therapeutic Concentration of Drugs -- 1.5 Toxic Concentration of Drugs -- 1.6 Conclusion -- References -- 2: Analytical Techniques for Therapeutic Drug Monitoring and Clinical Toxicology -- 2.1 Introduction -- 2.2 Immunoassays -- 2.3 Electrophoresis -- 2.4 Biosensors -- 2.5 Conventional HPLC and Emerging UHPLC Techniques -- 2.6 Gas Chromatography (GC) -- 2.7 Conclusion and Outlook -- References -- 3: Plasma Therapeutic Drug Monitoring and Clinical Toxicology -- 3.1 Overview of Therapeutic Drug Monitoring (TDM) -- 3.1.1 Assumptions -- 3.1.2 Process of Therapeutic Drug Monitoring -- 3.2 Indications for Measuring Plasma Concentrations -- 3.2.1 Avoiding or Diagnosing Toxicity -- 3.2.2 Diagnosing Undertreatment and Monitoring Patient Adherence -- 3.2.3 Prophylaxis -- 3.2.4 Drug Interactions and Termination of Treatment -- 3.3 Proper Use of Measurements -- 3.3.1 Timing of Blood Samples -- 3.3.2 Type of Sample Used -- 3.3.3 Measurement Technique -- 3.3.4 Individualization of Results -- 3.4 Individualizing Therapy -- 3.4.1 Formulation and Diet -- 3.4.2 Pharmacokinetics: Ion Trapping -- 3.4.3 Pathologic Disease States -- 3.4.4 Cytochrome P450 Enzymes -- 3.4.5 Age -- 3.5 Serum Versus Plasma Monitoring -- 3.5.1 Drugs Requiring Monitoring: Digoxin -- 3.5.2 Drugs Requiring Monitoring: Phenytoin -- 3.6 Renal Clearance and Metabolism in Therapeutic Drug Monitoring -- 3.6.1 Critically Ill Patients -- 3.6.2 Geriatric Patients -- 3.6.3 Pediatric Patients.
3.6.4 Acute or Chronic Renal Failure Patients -- 3.7 Role of Cytochrome P450 Systems in Liver Clearance and Metabolism -- 3.7.1 Acetaminophen -- 3.7.2 Rifampin -- 3.7.3 Erythromycin -- 3.8 Antiretrovirals and Glucose in Therapeutic Drug Monitoring -- 3.8.1 The Role and Influence of Glucose in Therapeutic Drug Monitoring -- 3.8.2 Therapeutic Drug Monitoring of Antiretroviral Drugs -- 3.9 Conclusion -- References -- 4: Dried Blood Spots in Therapeutic Drug Monitoring and Toxicology -- 4.1 Introduction -- 4.2 Therapeutic Drug Monitoring (TDM) -- 4.2.1 DBS in PK Monitoring -- 4.2.2 Factors to Consider in PK Studies Using DBS Sampling -- 4.2.3 Toxicology -- 4.2.3.1 Toxicokinetics -- 4.2.3.2 Forensic Toxicology -- 4.2.3.3 Screening for Environmental Contaminants -- 4.3 The Hematocrit Factor -- 4.3.1 Holistic Analysis of Volumetrically Spotted DBS -- 4.3.2 Use of DPS in Place of DBS -- 4.3.3 Use of Special Filter Substrates -- 4.3.4 Use of Hematocrit Calibrators -- 4.3.5 Estimation or Prediction of Hematocrit -- 4.4 General Steps in DBS Sampling -- 4.4.1 Selection of Filter Material -- 4.4.2 Collection of Specimen -- 4.4.3 Drying of Spotted Cards -- 4.4.4 Packaging of DBS for Storage and Transport -- 4.4.5 Extraction and Analysis of Analyte -- 4.4.6 Validation of DBS-Based Analytical Processes -- 4.5 Recent Innovative DBS Sampling Alternatives -- 4.6 High-Throughput Application of DBS Sampling -- 4.7 Conclusion and Future Perspectives -- References -- 5: The Role of Artificial Intelligence in Therapeutic Drug Monitoring and Clinical Toxicity -- 5.1 Introduction -- 5.2 AI Terms -- 5.2.1 Machine Learning (ML) -- 5.2.2 Deep Learning (DL) -- 5.2.3 Artificial Neural Network (ANN) -- 5.3 Implementing AI in Drug Design: Early Stages -- 5.4 Essentials for Implementing AI in Drug Discovery -- 5.4.1 Data Describing the System. 5.4.2 Integration of Data -- 5.4.3 System Stability -- 5.4.4 Dimension and Interdependency -- 5.4.5 Field Knowledge -- 5.5 AI or Ligand Discovery: Which One Is Critical in Drug Discovery? -- 5.6 AI in Drug Monitoring: Gathering Medical Big Data -- 5.7 Pipeline for Disease Monitoring -- 5.7.1 Target Selection, Validation -- 5.7.2 Design, Optimization of Drug Design -- 5.7.3 Clinical Studies (Virtual) -- 5.8 AI in Pharmacovigilance -- 5.9 AI in Toxicity -- 5.10 Structural Toxicity for Endpoints -- 5.10.1 Toxicity for Multiple-Time Point Assays -- 5.11 AI for Drug Safety: Recent Advances and Post-Market Surveillance -- 5.12 Illusions and Reality of AI in Drug Design -- 5.13 Future of AI in Drug Design -- 5.14 Conclusions -- References -- 6: Therapeutic Drug Monitoring and Optimal Pharmacotherapy with Medicines of Narrow Therapeutic Index -- 6.1 Background -- 6.2 Therapeutic Drug Monitoring -- 6.3 Medicines That Are Known to Require Therapeutic Drug Monitoring -- 6.4 Medication Therapy That Requires TDM for Optimal Outcomes -- 6.5 Guidelines for Sample Collection -- 6.6 Timing of Plasma Sample for TDM -- 6.7 Request for Therapeutic Drug Monitoring -- 6.8 Therapeutic Drug Monitoring and Interpretation of Results -- 6.9 Medications That May Benefit from Therapeutic Drug Monitoring -- 6.10 Techniques for Measurement of Therapeutic Drug Monitoring -- 6.11 Practical Use of Therapeutic Drug Monitoring -- References -- 7: Therapeutic Drug Monitoring (TDM) and Toxicological Studies in Alternative Biological Matrices -- 7.1 Introduction -- 7.2 Therapeutic Drug Monitoring (TDM) -- 7.2.1 Purpose of Therapeutic Drug Monitoring (TDM) -- 7.2.2 TDM: Estimating Plasma Drug Concentration -- 7.2.3 TDM Analytical Issues -- 7.2.4 Practical Issues in TDM -- 7.2.5 TDM's Translational Challenges -- 7.2.6 Recent Advances in TDM Practice. 7.2.6.1 Chromatographic Methods -- 7.2.6.2 Immunoassays -- 7.2.6.3 Biosensors -- 7.2.6.4 Biochips -- 7.3 Science of Toxicology -- 7.3.1 Toxicology: Biological Sampling and Use of Different Analytical Techniques -- 7.3.1.1 Reasons for Testing -- 7.3.1.2 Pharmacologic Reasons -- 7.3.1.3 Pharmacokinetic Reasons -- 7.3.1.4 Availability of Specimens -- 7.3.1.5 Ease of Collection -- 7.4 Alternative Matrices in Toxicology -- 7.5 Different Approaches in Various Biological Matrices, with an Emphasis on Toxicology -- 7.5.1 Microextraction Techniques in Different Biological Matrices -- 7.5.2 Other Green Extraction Technique Application -- 7.5.3 Applications of Mass Spectrometry Techniques in Alternative Biological Matrices -- 7.6 Artificial Intelligence (AI) in Toxicity and Drug Discovery -- 7.7 Promises and Pitfalls of Alternative Matrices -- 7.8 Artificial Intelligence (AI) in Toxicology and TDM -- 7.8.1 Artificial Intelligence for Clinical Toxicity and Patient Safety -- 7.8.2 Artificial Intelligence (AI) in the Prediction of Adverse Drug Reaction (ADR) and a Case Study -- 7.9 Importance and Future Perspective of TDM -- 7.10 Challenges Faced in Managing Patient Health Data -- 7.11 Conclusions -- References -- 8: Analyzing Data from Therapeutic Drug Monitoring, Pharmacokinetics, and Clinical Toxicology Studies -- 8.1 Introduction -- 8.1.1 Software Setup -- 8.2 Endpoints -- 8.3 Types of Data -- 8.4 Data Handling -- 8.5 Pharmacokinetics -- 8.5.1 Single-Dose PK Parameters -- 8.5.1.1 Cmax and tmax -- 8.5.1.2 AUCt -- 8.5.1.3 λ and t1/2 -- 8.5.1.4 AUC∞ -- 8.5.1.5 CL/F and Vd/F -- 8.5.2 Steady-State PK Parameters -- 8.5.2.1 Cav,SS and CSS -- 8.5.2.2 Ctrough and Cmax,SS -- 8.6 Pharmacodynamics -- 8.6.1 PK/PD -- 8.7 Descriptive and Inferential Statistics -- 8.7.1 Statistical Hypothesis Testing -- 8.7.1.1 Type I Error. 8.7.1.2 Type II Error -- 8.7.1.3 Significance Testing and p-Value -- 8.7.2 Confidence Interval (CI) -- 8.8 Sample Size and Power -- 8.9 Analysis Methods -- 8.9.1 Categorical Endpoints/Comparison of Proportions -- 8.9.1.1 Chi-Square Test -- 8.9.1.2 Fisher's Exact Test -- 8.9.1.3 McNemar Test -- 8.9.1.4 Logistic Regression -- 8.9.2 Continuous Endpoints/Comparison of Means -- 8.9.2.1 One-Sample T-Test -- 8.9.2.2 One-Sample Wilcoxon Test -- 8.9.2.3 Independent T-Test -- 8.9.2.4 Wilcoxon Rank Sum (Mann-Whitney U) Test -- 8.9.2.5 Paired T-Test -- 8.9.2.6 Wilcoxon Signed Rank Test -- 8.9.2.7 Linear Regression -- 8.9.2.8 Analysis of Variance (ANOVA) -- 8.9.2.9 Kruskal-Wallis Test -- References -- 9: Reducing Toxicity in Critically Ill Patients by Using Therapeutic Drug Monitoring -- 9.1 Introduction -- 9.1.1 Critically Ill Patients -- 9.1.2 Therapeutic Drug Monitoring -- 9.2 Antimicrobial Agents -- 9.2.1 General Pharmacokinetics (PK)/Pharmacodynamics (PD) Targets -- 9.2.2 Antibacterial Agents/Antibiotics -- 9.2.2.1 Aminoglycosides -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.2.2 ß-Lactams -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.2.3 Fluoroquinolones -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.2.4 Vancomycin -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.2.5 Linezolid -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.3 Antifungal Agents -- 9.2.3.1 Fluconazole -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.3.2 Flucytosine -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.4 Antiviral Agents -- 9.2.4.1 Acyclovir/Valacyclovir -- PK/PD Targets -- Dose Adjustment Strategies -- Bioanalytical Assay -- 9.2.4.2 Ribavirin. PK/PD Targets. |
| Record Nr. | UNINA-9910624383203321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Resolving erroneous reports in toxicology and therapeutic drug monitoring [[electronic resource] ] : a comprehensive guide / / Amitava Dasgupta
| Resolving erroneous reports in toxicology and therapeutic drug monitoring [[electronic resource] ] : a comprehensive guide / / Amitava Dasgupta |
| Autore | Dasgupta Amitava <1958-> |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (467 p.) |
| Disciplina | 615.7/040724 |
| Soggetto topico | Drug monitoring |
| ISBN |
1-280-99834-2
9786613769954 1-118-34785-4 1-118-34786-2 1-118-34783-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | An introduction to tests performed in toxicology laboratories and methodologies available for such testings -- Challenges in drugs of abuse testing -- False positive results in immunoassays for drugs of abuse testing -- True positive drugs of abuse test results due to prescription and non-prescription drugs -- When toxicology report is negative in a suspected overdosed patient : the world of designer drugs -- Abuse of magic mushroom, peyote cactus and solvent : no readily available laboratory tests -- False positive alcohol tests using breath analyzers and automated analyzers -- Role of laboratory in detecting other poisoning including pesticides, ethylene glycol, and methanol -- Poisoning with warfarin and superwarfarin : what laboratory can do? -- Plant poisoning and clinical laboratory -- Sources of erroneous results in therapeutic drug monitoring due to pre-analytical errors, high bilirubin, hemolysis, and heterophilic antibody -- Interferences in immunoassays used for digoxin monitoring -- Interferences in immunoassays used for monitoring anticonvulsants and usefulness of monitoring free anticonvulsants in certain patients -- Interferences in immunoassays used for monitoring tricyclic antidepressant -- Therapeutic drug monitoring of immunosuppressant drugs : limitations of immunoassays and need for chromatographic methods -- Effect of drug-herb interactions on therapeutic drug monitoring -- Pharmacogenomics and toxicology laboratory -- Approaches for eliminating interference/discordant specimen in therapeutic drug monitoring and drugs of abuse testing. |
| Record Nr. | UNINA-9910141255303321 |
Dasgupta Amitava <1958->
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Resolving erroneous reports in toxicology and therapeutic drug monitoring : a comprehensive guide / / Amitava Dasgupta
| Resolving erroneous reports in toxicology and therapeutic drug monitoring : a comprehensive guide / / Amitava Dasgupta |
| Autore | Dasgupta Amitava <1958-> |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (467 p.) |
| Disciplina | 615.7/040724 |
| Soggetto topico | Drug monitoring |
| ISBN |
1-280-99834-2
9786613769954 1-118-34785-4 1-118-34786-2 1-118-34783-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | An introduction to tests performed in toxicology laboratories and methodologies available for such testings -- Challenges in drugs of abuse testing -- False positive results in immunoassays for drugs of abuse testing -- True positive drugs of abuse test results due to prescription and non-prescription drugs -- When toxicology report is negative in a suspected overdosed patient : the world of designer drugs -- Abuse of magic mushroom, peyote cactus and solvent : no readily available laboratory tests -- False positive alcohol tests using breath analyzers and automated analyzers -- Role of laboratory in detecting other poisoning including pesticides, ethylene glycol, and methanol -- Poisoning with warfarin and superwarfarin : what laboratory can do? -- Plant poisoning and clinical laboratory -- Sources of erroneous results in therapeutic drug monitoring due to pre-analytical errors, high bilirubin, hemolysis, and heterophilic antibody -- Interferences in immunoassays used for digoxin monitoring -- Interferences in immunoassays used for monitoring anticonvulsants and usefulness of monitoring free anticonvulsants in certain patients -- Interferences in immunoassays used for monitoring tricyclic antidepressant -- Therapeutic drug monitoring of immunosuppressant drugs : limitations of immunoassays and need for chromatographic methods -- Effect of drug-herb interactions on therapeutic drug monitoring -- Pharmacogenomics and toxicology laboratory -- Approaches for eliminating interference/discordant specimen in therapeutic drug monitoring and drugs of abuse testing. |
| Record Nr. | UNINA-9910807170403321 |
|
Dasgupta Amitava <1958->
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Reviews in pharmaceutical and biomedical analysis [[electronic resource] /] / editors, Paraskevas D. Tzanavaras & Constantinos K. Zacharis
| Reviews in pharmaceutical and biomedical analysis [[electronic resource] /] / editors, Paraskevas D. Tzanavaras & Constantinos K. Zacharis |
| Pubbl/distr/stampa | [S.l.], : Bentham e Books, [2010] |
| Descrizione fisica | 1 online resource (160 p.) |
| Disciplina | 600 |
| Altri autori (Persone) |
TzanavarasParaskevas D
ZacharisConstantinos K |
| Soggetto topico |
Drugs - Analysis
Drug monitoring |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-60805-190-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 01 Title.pdf; 02 Cover Page; 03 eBooks End User License Agreement-Website; 05 Forward; 06 Preface; 07 List of contributors; 08 Chapter 1 _Andrade_; 09 Chapter 2 _Loukas_ revised; 10 Chapter 3 _Mauri_ revised; 11 Chapter 4 _Xu_ revised; 12 Chapter 5 _O'Kennedy_; 13 Chapter 6 _Kauffmann_; 14 Chapter 7 _Samanidou_ revised; 15 Chapter 8 _Starek_ revised; 16 Chapter 9 _Tan_ revised; 17 Chapter 10 _Li_; 18 INDEX |
| Record Nr. | UNINA-9910458887603321 |
| [S.l.], : Bentham e Books, [2010] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Reviews in pharmaceutical and biomedical analysis / / editors, Paraskevas D. Tzanavaras & Constantinos K. Zacharis
| Reviews in pharmaceutical and biomedical analysis / / editors, Paraskevas D. Tzanavaras & Constantinos K. Zacharis |
| Pubbl/distr/stampa | [S.l.], : Bentham e Books, [2010] |
| Descrizione fisica | 1 online resource (v, 151 pages) : illustrations |
| Disciplina | 600 |
| Altri autori (Persone) |
TzanavarasParaskevas D
ZacharisConstantinos K |
| Soggetto topico |
Drugs - Analysis
Drug monitoring Drugs - Side effects - Reporting |
| ISBN | 1-60805-190-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 01 Title.pdf; 02 Cover Page; 03 eBooks End User License Agreement-Website; 05 Forward; 06 Preface; 07 List of contributors; 08 Chapter 1 _Andrade_; 09 Chapter 2 _Loukas_ revised; 10 Chapter 3 _Mauri_ revised; 11 Chapter 4 _Xu_ revised; 12 Chapter 5 _O'Kennedy_; 13 Chapter 6 _Kauffmann_; 14 Chapter 7 _Samanidou_ revised; 15 Chapter 8 _Starek_ revised; 16 Chapter 9 _Tan_ revised; 17 Chapter 10 _Li_; 18 INDEX |
| Record Nr. | UNINA-9910785596003321 |
| [S.l.], : Bentham e Books, [2010] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
